Skip to main content
logo
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.360
-0.040 (-2.86%)
At close: May 29, 2026, 4:00 PM EDT
1.380
+0.020 (1.47%)
After-hours: May 29, 2026, 6:51 PM EDT

Metagenomi Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-85.89-87.87-78.06-68.26-43.59-21.44
Depreciation & Amortization
5.235.325.414.211.730.39
Stock-Based Compensation
11.4811.8516.26.921.960.38
Other Adjustments
3.953.97.04-7.850.14-1.32
Change in Receivables
1.010.951.19-2.45--
Changes in Accounts Payable
-0.361.05-1.11-0.080.720.7
Changes in Accrued Expenses
-1.02-1.64-0.891.634.531.85
Changes in Income Taxes Payable
---3.271.731.54-
Changes in Unearned Revenue
-18.8-21.1-46.8-30.365.6644.23
Changes in Other Operating Activities
-3.57-1.36-8.793.04-2.96-0.52
Operating Cash Flow
-87.23-88.89-109.07-91.4129.7224.26
Operating Cash Flow Growth
----22.54%-
Capital Expenditures
-0.31-0.57-3.11-9.81-13.98-2.9
Sale of Property, Plant & Equipment
0.020.04----
Purchases of Investments
-80.87-66.41-306.42-208.1-214.85-71.41
Proceeds from Sale of Investments
163.93170.47221.38263.64106.63-
Investing Cash Flow
82.79103.53-88.1645.73-122.2-74.32
Issuance of Common Stock
0.150.284.01---
Net Common Stock Issued (Repurchased)
0.150.284.01---
Issuance of Preferred Stock
---4.3239.599.95
Net Preferred Stock Issued (Repurchased)
---4.3239.599.95
Other Financing Activities
-0.51-0.56--3.28-29.97
Financing Cash Flow
-0.31-0.3684.011.01239.5939.92
Net Cash Flow
-4.7414.28-113.22-44.66147.12-10.14
Free Cash Flow
-87.54-89.47-112.19-101.2215.7521.35
Free Cash Flow Growth
-----26.26%-
FCF Margin
-391.99%-354.88%-214.53%-226.17%91.55%8787.65%
Free Cash Flow Per Share
-2.34-2.40-3.40-29.734.636.27
Levered Free Cash Flow
-104.71-106.17-136.63-97.8413.6522.3
Unlevered Free Cash Flow
-111.45-114.25-141.61-118.549.8119.79
SEC Filings: 10-K · 10-Q